干扰素α-2b联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎近期疗效观察

The short-term efficacy and safety of interferon alfa-2b in combination with adefovir dipivoxil in treatment of patients with HBeAg positive chronic hepatitis B

目的探讨干扰素α-2b联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的近期疗效及安全性。方法将HBeAg阳性慢性乙型肝炎患者随机分为单药治疗组(40例)和联合治疗组(42例),分别应用干扰素α-2b单药治疗或联合阿德福韦酯抗病毒治疗,疗程48周。结果在治疗结束时,联合治疗组ALT复常率为85.7%,HBVDNA阴转率为71.4%,HBeAg转阴率为61.9%,HBeAg血清学转换率为45.2%,均显著高于单药治疗组(分别为60.0%、45.0%、37.5%、25.0%,P<0.05);联合治疗组不良反应发生率与单药治疗组比无统计学差异(P>0.05)。结论干扰素联合阿德福韦酯可提高慢性乙型肝炎抗病毒疗效且安全性良好。

Objective To compare the efficacy and safety of interferon alfa-2b in combination with adefovir dipivoxil and interferon monotherapy in patients with HBeAg positive chronic hepatitis B. Methods A total of 82 patients with HBeAg positive chronic hepatitis B were randomized into two groups receiving interferon（monotherapy, n=40） and interferon plus adefovir dipivoxil （combination,n=42） for 48 weeks. Results The rates of serum ALT normalization（85.7%）,HBV DNA loss （71.4%）,HBeAg negativity（61.9%） and HBeAg seroconversion（45.2%） in combination therapy group were higher than those in monotherapy group （60.0%,45.0%,37.5%,25.0%, respectively, P〈0.05）;combination therapy did not increase the occurrence of adverse events （P〉0.05）.Conclusion The efficacy and safety of interferon alfa-2b in combination with adefovir dipivoxil treatment for HBeAg positive chronic hepatitis B patients seems to be better than that in interferon alfa-2b monotherapy.